Tag: Ebvallo

Clinical trials show that tabelecleucel can achieve objective response rates of over 50% in patients with relapsed or refractory EBV+ PTLD. For those with this aggressive disease, understanding **how does tabelecleucel work** reveals a targeted approach using donor T-cells to specifically eliminate EBV-infected cells that drive the condition.

Over half of all relapsed or refractory EBV+ PTLD cases after initial treatment have poor outcomes and limited therapeutic options, highlighting a significant unmet medical need. **What is the mechanism of action of Ebvallo?** Ebvallo is an allogeneic, off-the-shelf T-cell immunotherapy that directly addresses this by selectively targeting and eliminating EBV-infected cells.